Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients

[1]  C. Yi,et al.  ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma , 2020, Medicine.

[2]  Yubei Huang,et al.  Association of ABO polymorphisms and pancreatic Cancer/ Cardiocerebrovascular disease: a meta-analysis , 2020, BMC Medical Genetics.

[3]  Edward J. Kim,et al.  Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. , 2020, The lancet. Gastroenterology & hepatology.

[4]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[5]  H. Ohira,et al.  Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis , 2019, Cancer Chemotherapy and Pharmacology.

[6]  H. Ueno,et al.  Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease , 2019, PloS one.

[7]  A. Gemma,et al.  Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer , 2018, Japanese journal of clinical oncology.

[8]  G. Lahat,et al.  Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  N. Kato,et al.  Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer Patients. , 2018, Pancreas.

[10]  A. Gemma,et al.  Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis , 2017, Japanese journal of clinical oncology.

[11]  R. Caruso,et al.  Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  D. Jäger,et al.  Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients , 2016, Annals of surgery.

[13]  T. Conroy,et al.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.

[14]  T. Mukohara,et al.  The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer , 2016, Cancer Chemotherapy and Pharmacology.

[15]  H. Yasunaga,et al.  Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study , 2016, Respirology.

[16]  Feng Zhu,et al.  Association between ABO gene polymorphism (rs505922) and cancer risk: a meta-analysis , 2015, Tumor Biology.

[17]  A. Gemma,et al.  Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer , 2014, Cancer science.

[18]  H. Risch,et al.  Re-evaluation of ABO gene polymorphisms detected in a genome-wide association study and risk of pancreatic ductal adenocarcinoma in a Chinese population , 2014, Chinese journal of cancer.

[19]  Na He,et al.  ABO blood groups and risk of cancer: a systematic review and meta-analysis. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[20]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[21]  Sachiko Tanaka,et al.  Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan. , 2013, Japanese journal of clinical oncology.

[22]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[23]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[24]  J. Furuse,et al.  Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer , 2011, Cancer science.

[25]  E. Rimm,et al.  Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. , 2010, Human molecular genetics.

[26]  A. Hofman,et al.  Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. , 2010, Human molecular genetics.

[27]  Geoffrey S. Tobias,et al.  Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer , 2009, Nature Genetics.

[28]  P. Ridker,et al.  Novel Association of ABO Histo-Blood Group Antigen with Soluble ICAM-1: Results of a Genome-Wide Association Study of 6,578 Women , 2008, PLoS genetics.

[29]  Mark I. McCarthy,et al.  A Genome-Wide Association Study Identifies Protein Quantitative Trait Loci (pQTLs) , 2008, PLoS genetics.

[30]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.